Literature DB >> 3261203

In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells.

A A Maghazachi1, R B Herberman, N L Vujanovic, J C Hiserodt.   

Abstract

A highly purified population of effector lymphokine-activated killer (LAK) cells was generated by culturing nylon-wool column nonadherent rat splenocytes in the presence of interleukin 2 (IL-2), and the cells which became adherent to the plastic flasks were separated and maintained in culture for a total of 5 days. More than 95% of these cells had the morphology of large granular lymphocytes (LGL), expressed surface phenotypes characteristic of rat natural killer (NK) cells, and were able to kill NK-sensitive and NK-resistant tumor target cells. 51Cr-labeled purified A-LAK cells injected intravenously into syngeneic F344 rats localized primarily in the lungs 2 hr after injection but then redistributed to the liver and the spleen by 24 hr after injection. The effects of various immunological manipulations on the distribution pattern of the isolated LAK cells were evaluated. Treatment of the host with 500 rad total body X-irradiation 24 hr before cell injection resulted in an early uptake of LAK cells into the liver and the spleen, whereas treatment with cyclophosphamide 1 day before cell injection, resulted in an early uptake of LAK cells into the liver but not into the spleen. Treatment of the recipient rats with up to 120,000 units recombinant interleukin-2 intraperitoneally did not result in the accumulation of LAK cells at the site of IL-2 injection, nor did it result in a modulation of the overall distribution pattern or total recovery of radiolabeled LAK cells. Rather, the administration of IL-2 was necessary to maintain the cytotoxic activity of the injected LAK cells isolated from the liver and spleen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261203     DOI: 10.1016/0008-8749(88)90172-4

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  14 in total

1.  Confusion about the tissue distribution of lymphokine-activated killer (LAK) cells.

Authors:  A A Maghazachi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels.

Authors:  P Basse; R B Herberman; M Hokland; R H Goldfarb
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors.

Authors:  A A Maghazachi
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

4.  Surveillance of systemic trafficking of macrophages induced by UHMWPE particles in nude mice by noninvasive imaging.

Authors:  Pei-Gen Ren; Zhinong Huang; Ting Ma; Sandip Biswal; Robert L Smith; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2010-09-01       Impact factor: 4.396

5.  Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma.

Authors:  E Schäfer; R Dummer; C Eilles; W Börner; R Martin; J Rendl; G Burg
Journal:  Eur J Nucl Med       Date:  1991

6.  Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.

Authors:  P Zanovello; A Rosato; V Bronte; S Mandruzzato; V Cerundolo; D Collavo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Systemic trafficking of macrophages induced by bone cement particles in nude mice.

Authors:  Pei-Gen Ren; Sheen-Woo Lee; Sandip Biswal; Stuart B Goodman
Journal:  Biomaterials       Date:  2008-09-27       Impact factor: 12.479

8.  Dual reporter gene imaging for tracking macrophage migration using the human sodium iodide symporter and an enhanced firefly luciferase in a murine inflammation model.

Authors:  Ho Won Lee; Yong Hyun Jeon; Mi-Hye Hwang; Jung-Eun Kim; Tae-in Park; Jeoung-Hee Ha; Sang-Woo Lee; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

9.  Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markers.

Authors:  A A Maghazachi; L Fitzgibbon
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.

Authors:  Y F Zhai; W J Esselman; C S Oakley; C C Chang; C W Welsch
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.